Roche Likes Its Critical Mass But Could Amass More; $2 Bil. R&D Will Do

Roche's restructuring and internal growth obviates the need for a merger, even with the recent loss of several late-phase clinical projects, CEO Franz Humer told the Roche 1999 annual earnings conference March 30 in Basel.